Texas Retina Associates’ Ashkan M. Abbey, MD, is presenting this week at the 40th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in New York City. ASRS is the largest organization of retina specialists in the world with over 3,000 members in all 50 U.S. states, the District of Columbia, Puerto Rico, and 63 countries.
Dr. Abbey is speaking about “Injectable Fluocinolone Implant for the Management of Chronic Post-surgical Uveitis and Cystoid Macular Edema.” Long-acting injectable steroids are changing the treatment paradigm for patients with chronic intraocular inflammation, and Dr. Abbey will report on outcomes of the intravitreal injectable 0.18 mg fluocinolone implant (FAI) for the management of inflammation and cystoid macular edema (CME) in patients with chronic post-surgical uveitis. He is sharing a retrospective case series of 23 patients and 24 eyes, all of which underwent prior pars plana vitrectomy (PPV), a surgical procedure where the vitreous (the gel-like fluid that fills the eye between the lens and retina) is removed to allow access to the posterior segment of the eye, and subsequently received FAI.
Highlights of Dr. Abbey’s findings include the following:
- FAI can be an effective treatment in patients with chronic post-surgical inflammation and CME.
- Although there was no significant change in visual acuity, there was improvement in the level of intraocular inflammation and CME.